KRASG12D
42 programs · 42 companies
Programs
42
Companies
42
Active Trials
21
Targeting KRASG12D
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | Alzheimer's | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | Hemophilia ADLBCL | |
| SNY-2934 | Sanofi | Phase 3 | ADHD | |
| Talainavolisib | Novo Nordisk | Preclinical | WMADHD | |
| GIL-2037 | Gilead Sciences | Approved | CLLLN | |
| NBI-408 | Neurocrine | Phase 2/3 | Breast Ca | |
| 207-2754 | Samsung Biologics | Phase 1/2 | Heart FailureGBM | |
| SLR-5251 | Acelyrin | Phase 3 | AngelmanADPKD | |
| CSL-4459 | CSL Limited | NDA/BLA | MSGBM | |
| 451-5171 | Chugai | Preclinical | GISTCLL | |
| 452-3353 | Ono Pharma | Preclinical | T2DCF | |
| Nidatenlimab | Sun Pharma | NDA/BLA | CLLBreast Ca | |
| TLX-9433 | Telix Pharma | Phase 2 | NSCLC | |
| Zanulemzoparlimab | Aurinia | NDA/BLA | CFSchizophrenia | |
| MD-IIT-841 | MD Anderson | Phase 1 | CLL | |
| FRE-IIT-743 | Fred Hutch Cancer Ctr | NDA/BLA | Gastric Ca | |
| GIM-IIT-532 | GIMEMA | Phase 1/2 | SCD | |
| Sotofutibatinib | Karuna (BMS) | Phase 1/2 | Myelofibrosis | |
| TNY-3110 | Tenaya | Preclinical | Alzheimer'sALL | |
| UPB-4925 | Upstream Bio | Phase 2/3 | OCDMM | |
| Sovalemzoparlimab | OncoBiologics | Phase 2/3 | GIST | |
| Sovafotisoran | Corvus Pharma | Preclinical | PBCBCC | |
| PBL-3756 | Panbela Therapeutics | Phase 1/2 | PVPancreatic Ca | |
| Polazumab | Adlai Nortye | Phase 3 | CRCIgAN | |
| BIO-6952 | BioNova Pharma | NDA/BLA | FTDTTR Amyloidosis | |
| ACC-8527 | Acceleron (Merck) | Approved | MDDNMOSD | |
| Doxazasiran | Principia (Sanofi) | Preclinical | RB | |
| 145-403 | Hugel | Phase 1/2 | Atopic Derm | |
| BIG-7200 | BigHat Bio | Phase 1 | ASMigraine | |
| Tezecapivasertib | Kojin Ther | Phase 1/2 | RettALL | |
| Lirazasiran | Vectura (PMI) | Phase 3 | Hemophilia ACF | |
| MRK-876 | Merck KGaA | Preclinical | MS | |
| Lirazumab | Plurilock | Phase 1 | ObesitySMA | |
| ORP-8634 | Orphazyme | Phase 1/2 | CFHuntington's | |
| Gelilemzoparlimab | Italfarmaco | Approved | ObesityMDD | |
| Kemanesiran | Camurus | Phase 3 | MDS | |
| PRI-IIT-560 | Princess Margaret | Phase 1/2 | TTR Amyloidosis | |
| AII-IIT-540 | AIIMS New Delhi | Phase 1/2 | NASH | |
| KIN-IIT-636 | King Faisal Spec Hosp | Phase 3 | Endometrial Ca | |
| 600-3422 | Zhejiang Hisun | Phase 1 | ADHDProstate Ca | |
| WAT-1779 | Waters Corp | Phase 1 | PVMeso | |
| ELA-1012 | Elanco | NDA/BLA | NMOSDHeart Failure |